There are several dual enkephalinase inhibitors currently under clinical trials show promising results in their preclinical studies [1]; especially orally administered P37 [36] which has potential to replace opioid pain management protocols in diabetic neuropathy. The gene discussed is MME; the disease is diabetic neuropathy.